Cover for Anti-Angiogenesis Strategies in Cancer Therapies

Anti-Angiogenesis Strategies in Cancer Therapies

Book2017

Edited by:

Shaker A. Mousa and Paul J. Davis

Anti-Angiogenesis Strategies in Cancer Therapies

Book2017

 

Cover for Anti-Angiogenesis Strategies in Cancer Therapies

Edited by:

Shaker A. Mousa and Paul J. Davis

Browse this book

Book description

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis ... read full description

Browse content

Table of contents

Actions for selected chapters

Select all / Deselect all

  1. Full text access
  2. Book chapterAbstract only

    Chapter 1 - Angiogenesis and Anti-Angiogenesis Strategies in Cancer

    Shaker A. Mousa and Paul J. Davis

    Pages 1-19

  3. Book chapterAbstract only

    Chapter 2 - Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques

    Shaker A. Mousa, Murat Yalcin and Paul J. Davis

    Pages 21-38

  4. Book chapterAbstract only

    Chapter 3 - Anti-Angiogenesis in Multiple Myeloma

    Domenico Ribatti and Angelo Vacca

    Pages 39-50

  5. Book chapterAbstract only

    Chapter 4 - Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression

    Shaker A. Mousa, Vandhana Muralidharan-Chari and Paul J. Davis

    Pages 51-68

  6. Book chapterAbstract only

    Chapter 5 - microRNAs and Angiogenesis

    Paul J. Davis, Matthew Leinung and Shaker A. Mousa

    Pages 69-84

  7. Book chapterAbstract only

    Chapter 6 - Naturally Occurring Angiogenesis Inhibitors

    Shaker A. Mousa, Maii Abu Taleb and Paul J. Davis

    Pages 85-97

  8. Book chapterAbstract only

    Chapter 7 - Integrin Antagonists and Angiogenesis

    Shaker A. Mousa, Noureldien H.E. Darwish and Paul J. Davis

    Pages 99-123

  9. Book chapterAbstract only

    Chapter 8 - Tyrosine Kinase Inhibitors and Angiogenesis

    Paul J. Davis and Shaker A. Mousa

    Pages 125-131

  10. Book chapterAbstract only

    Chapter 9 - Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis

    Paul J. Davis and Shaker A. Mousa

    Pages 133-146

  11. Book chapterAbstract only

    Chapter 10 - Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis

    Shaker A. Mousa, Thangirala Sudha and Paul J. Davis

    Pages 147-163

  12. Book chapterAbstract only

    Chapter 11 - Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics

    Dhruba J. Bharali, Mehdi Rajabi and Shaker A. Mousa

    Pages 165-178

  13. Book chapterAbstract only

    Chapter 12 - New Directions in Anti-Angiogenesis Research

    Shaker A. Mousa and Paul J. Davis

    Pages 179-186

  14. Book chapterNo access

    Index

    Pages 187-194

About the book

Description

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.

Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.

Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.

Key Features

  • Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
  • Reviews FDA-approved anti-angiogenesis agents
  • Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
  • Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
  • Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
  • Reviews FDA-approved anti-angiogenesis agents
  • Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
  • Offers insight into the development of novel anti-angiogenesis agents and future direction in this area

Details

ISBN

978-0-12-802576-5

Language

English

Published

2017

Copyright

Copyright © 2017 Elsevier Inc. All rights reserved.

Imprint

Academic Press

You currently don’t have access to this book, however you can purchase separate chapters directly from the table of contents or buy the full version.

Purchase the book

Editors

Shaker A. Mousa

The Pharmaceutical Research Institute
Albany College of Pharmacy and Health Sciences
Rensselaer, New York, United States

Paul J. Davis

Department of Medicine, Albany Medical College
Albany, New York, United States

The Pharmaceutical Research Institute
Albany College of Pharmacy and Health Sciences
Rensselaer, New York, United States